Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Acquisitions & Divestments (2020 - 2025)

Historic Change in Acquisitions & Divestments for BridgeBio Pharma (BBIO) over the last 6 years, with Q3 2025 value amounting to $8.0 million.

  • BridgeBio Pharma's Change in Acquisitions & Divestments fell 7481.98% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 9349.63%. This contributed to the annual value of $95.0 million for FY2024, which is 1407.07% down from last year.
  • Latest data reveals that BridgeBio Pharma reported Change in Acquisitions & Divestments of $8.0 million as of Q3 2025, which was down 7481.98% from $31.8 million recorded in Q3 2024.
  • BridgeBio Pharma's 5-year Change in Acquisitions & Divestments high stood at $186.7 million for Q1 2022, and its period low was $8.0 million during Q3 2025.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $63.2 million (2024), whereas its average is $71.6 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first skyrocketed by 24919.53% in 2021, then plummeted by 9025.68% in 2023.
  • BridgeBio Pharma's Change in Acquisitions & Divestments (Quarter) stood at $75.0 million in 2021, then tumbled by 64.17% to $26.9 million in 2022, then increased by 4.23% to $28.0 million in 2023, then grew by 13.44% to $31.8 million in 2024, then tumbled by 74.82% to $8.0 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $8.0 million for Q3 2025, versus $31.8 million for Q3 2024 and $63.2 million for Q1 2024.